- Home
- ALV vs BMRN Comparison
ALV vs BMRN Comparison
Compare ALV & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALV | BMRN |
|---|---|---|
| Founded | 1953 | 1996 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 10.0B |
| IPO Year | 1997 | 1999 |
Fundamental Metrics
Financial Performance| Metric | ALV | BMRN |
|---|---|---|
| Price | $120.69 | $51.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 19 |
| Target Price | ★ $133.45 | $88.42 |
| AVG Volume (30 Days) | 586.1K | ★ 3.0M |
| Earning Date | 01-30-2026 | 10-27-2025 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | 25.57 | ★ 59.53 |
| EPS | ★ 9.69 | 2.68 |
| Revenue | ★ $10,614,000,000.00 | $3,094,001,000.00 |
| Revenue This Year | $4.73 | $13.39 |
| Revenue Next Year | $4.40 | $7.57 |
| P/E Ratio | ★ $12.40 | $19.38 |
| Revenue Growth | 0.85 | ★ 12.39 |
| 52 Week Low | $75.49 | $50.76 |
| 52 Week High | $129.54 | $73.51 |
Technical Indicators
Market Signals| Indicator | ALV | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 54.24 | 39.53 |
| Support Level | $118.76 | $50.90 |
| Resistance Level | $122.90 | $53.57 |
| Average True Range (ATR) | 2.31 | 1.18 |
| MACD | 0.33 | -0.28 |
| Stochastic Oscillator | 67.32 | 19.07 |
Price Performance
Historical ComparisonAbout ALV Autoliv Inc.
Autoliv Inc is the world-wide leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.